ViiV Healthcare has started a Phase III study to examine a two-drug regimen (2DR) of dolutegravir (TIVICAY) and lamivudine (EPIVIR) for treating patients with HIV-1 who have achieved viral suppression on a tenofovir alafenamide fumarate (TAF) based regimen.

The TANGO trial aims to enrol around 550 adults with HIV-1 from clinical trial sites in North America, Europe, Australia, and Japan.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the trial, the subjects will be randomised 1:1 to switch to dolutegravir and lamivudine once-daily for up to 96 weeks, or to continue their TAF-based regimen for 48 weeks.

The patients in the TAF-based arm who achieve <50c/ml of HIV-1 RNA at week 48 of the trial will be switched to dolutegravir and lamivudine for the study’s remaining period.

Primary endpoint of the trial is the proportion of participants who meet the Snapshot virologic failure criteria at week 48 using the intent-to-treat exposed (ITT-E) population.

“This may allow healthcare providers to address issues of long-term toxicity by reducing exposure to antiviral agents over a lifetime of treatment.”

ViiV Healthcare chief scientific and medical officer John Pottage Jr said: “We are asking a simple question in the TANGO study: can virally suppressed people with HIV reduce the number of medicines in their HIV treatment regimen while maintaining viral suppression?

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“If the data show the answer to be yes, this may allow healthcare providers to address issues of long-term toxicity by reducing exposure to antiviral agents over a lifetime of treatment.

“We believe that with its high-barrier to resistance, dolutegravir has the right clinical profile to be a core part of 2DRs for the treatment of HIV-1 and look forward to seeing the results of TANGO in 2019.”

The TANGO study is based on ViiV’s GEMINI studies’ investigation of the 2DR of dolutegravir and lamivudine in treatment-naïve patients with HIV-1.

Trial results are expected later this year.